New immune therapy aims to tackle tough childhood leukemia
NCT ID NCT02443831
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This early-stage trial is testing a new type of immunotherapy for children and young adults with a high-risk or relapsed form of acute lymphoblastic leukemia. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells that carry two specific markers (CD19 and CD22). The study will enroll about 50 participants and will primarily look at safety and whether the treatment can clear the leukemia from the bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Great Ormond Street Hospital
RECRUITINGLondon, United Kingdom
Contact
-
Manchester Royal Children's Hospital
RECRUITINGManchester, United Kingdom
Contact
-
University College Hospital
RECRUITINGLondon, United Kingdom
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19+CD22 CAR T-cells (a type of immune cell therapy)
What this could lead to
If it works, this could offer a new treatment option for children with hard-to-treat leukemia that has come back or not responded to standard therapy.
What could go wrong
This is a very early (Phase 1) trial with only 50 participants, so it is not yet proven to be safe or effective. There are also risks of serious side effects from the chemotherapy and cell infusion.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.